Boson Medical Showcases 3D 4K Fluorescence Integrated Endoscopy Platform at CMEF, Supported by Over 10,000 Clinical Surgeries
Under the new international landscape and market environment, the world is being reshaped.
From the initial strategy of exchanging market access for technology to the exploration of independent innovation, China has launched a concerted push toward domestic substitution in mid-to-high-end medical devices, rapidly emerging as the world’s second-largest medical device market, valued at over one trillion yuan. In particular, the Chinese endoscopy market, once highly concentrated and dominated by international giants, is seeing its landscape reshaped by the innovative breakthroughs of domestic manufacturers.
In April 2024, the 89th China International Medical Equipment Fair (CMEF), themed “Innovative Technology, Leading the Future with Intelligence,” was successfully held in Shanghai. At the event, numerous domestic endoscopy companies unveiled their latest technological products, collectively demonstrating to both domestic and international audiences that Chinese-made endoscopes have gradually progressed from an initial stage of imitation to a globally leading position characterized by innovation and upgrading.
At this exhibition, Bosheng Medical, a national high-tech enterprise driven by independent R&D and technological innovation, prominently showcased its two leading products: the newly launched X1 Series 3D 4K Fluorescence Endoscopic Imaging Platform (hereinafter referred to as the “X1 Platform”) and the upgraded PX-850E Series 3D 4K Fluorescence Endoscopic Imaging Platform.
2024 CMEF Bosheng Medical Booth
Shenzhen Bosheng Medical Technology Co., Ltd. delivers a more precise, efficient, and integrated endoscopic imaging platform to the industry and market through breakthrough innovations in foundational technologies and designs that better align with clinical needs. This optimizes the allocation of medical resources, enhances patient care experiences, and supports the advancement of new quality productive forces in healthcare.
Since its inception in the 19th century, the medical endoscope has undergone continuous development and has become one of the indispensable medical devices for minimally invasive surgery in modern medicine.
Each leapfrog innovation and iteration in the industry stems from layer-by-layer breakthroughs in underlying technologies. In recent years, cutting-edge technologies such as 3D imaging, 4K resolution, fluorescence imaging, and artificial intelligence have been maturing, driving endoscopes toward greater functionality and higher clarity, while continuously expanding their application scenarios. As domestic endoscope manufacturers concentrate their efforts, various consensus statements and clinical guidelines have been successively introduced, providing clear guidance and direction for the development of domestically produced endoscopes.
For example, the 2019 edition“Chinese Expert Consensus on 3D Laparoscopic Surgical Techniques” and “Chinese Expert Consensus on 4K Laparoscopic Surgical Techniques”To establish standardized consensus opinions on indications, technical foundations, applications in various surgical procedures, technical advantages, and limitations of 3D/4K laparoscopic surgery; launched in 2020“Expert Consensus on the Clinical Evaluation System for Medical Endoscopes”It provides directions for the improvement and optimization of domestically produced endoscopes from various dimensions, points out the direction for the research, development, and innovation of high-end domestic laparoscopes, and promotes the widespread application of high-quality domestically produced medical endoscopes.
Evidently, technological, policy, and clinical factors are reshaping the endoscopy market. At the forefront of the industry, 4K technology that delivers “clear visualization” is a primary imperative and constitutes a fundamental capability of these products. Currently, over one hundred 4K rigid endoscope models have received regulatory approval for market launch; however, as high-definition endoscopic diagnostic and therapeutic techniques become increasingly widespread, clinical practice is placing greater demands on endoscope performance.
Traditional 2D endoscopes only display a planar view of the surgical field, lacking perception of stereoscopic and depth relationships between organs and tissues. In addition to clearly visualizing the surface of human tissues, 3D endoscopes can reveal the depth relationships between tissues and organs, thereby providing more accurate images for surgical procedures. While white-light endoscopy is limited to imaging the superficial layers of human tissues, fluorescence endoscopy enables visualization and imaging of sub-surface tissues under fluorescence guidance, thus enhancing the visibility of lesions and pre-lesional areas and facilitating precise intraoperative localization.
Evolving and upgrading clinical needs continue to drive innovation and iteration in endoscopic technologies. Currently, the integrated 3D, 4K, and fluorescence imaging technology has become the most advanced endoscopic imaging modality, offering multiple clinical advantages. It meets diverse clinical demands, significantly enhances the efficiency and safety of minimally invasive surgeries, and delivers greater benefits to patients.
As a pioneer and driver of the industry, Bosheng Medical has broken through technological barriers and taken a leading position in the global rigid endoscopy sector.
In early 2024, Bosheng Medical’s self-developed X1 3D 4K Fluorescence Endoscopy Imaging Platform (hereinafter referred to as the “X1 Platform”) officially obtained NMPA registration approval and was approved for market launch. The X1 Platform highly integrates 3D stereoscopic imaging, 4K resolution, and fluorescence technology. Notably, the X1 main unit adopts a domestically pioneering “ALL-IN-ONE” design, with the medical fluorescence cold light source and video recorder module built into the main unit, simplifying complexity and truly realizing the concept of an all-in-one system.
X1 3D 4K Fluorescence Endoscopy Imaging Platform
The ultimate goal and most significant value of medical device innovation lie in better serving clinical practice and patients. Therefore, whether an endoscope integrates multiple new technologies to enhance the level of clinical diagnosis and treatment has become a key criterion for evaluating its product competitiveness.
From a clinical value perspective, 3D technology addresses the limitations of traditional 2D imaging in spatial localization and hand-eye coordination. It faithfully reconstructs a stereoscopic three-dimensional surgical field, enabling surgeons to perceive depth binocularly during procedures and achieve true immersion.
3D 4K Fluorescence Ultra-High-Definition Electronic Thoraco-Laparoscope（Left）、4KFluorescence Optical Camera (Right）
How to avoid visual dizziness has always been a pain point that 3D endoscope manufacturers need to address, as well as a challenge in research and development. The team at Bosheng Medical has independently developed patented technology for adaptive stereoscopic perception, breaking through the fixed working distance of traditional 3D systems and thoroughly resolving issues of intraoperative dizziness and fatigue experienced by surgeons.
Empowered by its proprietary adaptive stereoscopic vision technology, the Bosheng 3D 4K Fluorescence Electronic Thoraco-Laparoscope effectively meets clinical needs, further highlighting its advantages in image acquisition, color reproduction, and the realism of 3D stereoscopic depth.
The X1 platform’s 4K optical camera supports lossless zoom and manual parfocal adjustment, maintaining sharp focus during forward and backward movements after parfocalization. This reduces the surgeon’s intraoperative workload, ensuring the image remains consistently within the optimal visual comfort zone.
To meet the requirements for intraoperative fluorescence imaging, the X1 platform supports nine modes, including black-and-white fluorescence, standard green fluorescence, standard blue fluorescence, and color fluorescence. These capabilities enable real-time intraoperative identification of the tumor lymphatic system, observation of tissue blood perfusion, and precise localization of tumor boundaries, thereby assisting clinicians in performing surgeries with greater precision and safety while significantly reducing surgical risks.
Whether using a fluorescence optical camera or a 3D fluorescence electronic endoscope, the prerequisite for precise imaging is the separation of white light and fluorescence at specific wavelengths. The accuracy of spectral splitting directly determines imaging quality and is critical to surgical outcomes and patient safety.
In response, when the camera simultaneously captures white light and fluorescence, Shenzhen Bosheng Medical Technology Co., Ltd. employs sub-micron alignment technology for precise dual-beam splitting, ensuring complete separation of white light and fluorescence signals without mutual interference. This approach has reached an internationally leading level, significantly enhancing imaging quality and accuracy.
Leveraging these advantages, the X1 platform meets the demands for high-definition imaging, stereoscopic vision, and precise localization during clinical endoscopic diagnosis and treatment. It reduces surgical difficulty, significantly shortens operative time, enhances surgical precision and efficiency, improves treatment quality, further alleviates surgeons’ workload, and optimizes patient outcomes.
Although Chinese endoscope manufacturers are striving to break into the global industry’s upper echelons, it is undeniable that the endoscopy market remains highly concentrated both domestically and internationally, with leading companies dominating the majority of the market.
To this end, government departments have promoted the development of domestically produced medical endoscopes from multiple dimensions, including research and development, certification, sales, and standardized usage. Starting in 2020, under the impetus of the National Medical Products Administration (NMPA), Class III endoscopes such as optical endoscopes were reclassified as Class II medical devices, significantly accelerating the registration process. Furthermore, various policies issued between the 12th Five-Year Plan and the 14th Five-Year Plan periods have supported independent innovation in domestically produced medical devices and encouraged medical institutions to procure them.
On the one hand, compared with traditional open surgery, endoscopy serves as a crucial enabler of minimally invasive surgical procedures. It is a medical device that integrates medical imaging systems with multiple advanced technologies. Minimally invasive surgeries performed via endoscopy can reduce postoperative pain and lower the risk of complications.
On the other hand, domestically produced endoscopes with higher cost-effectiveness have reduced hospitals' one-time procurement costs and subsequent operational expenses, thereby enhancing the accessibility of high-quality medical resources. Meanwhile, with improvements in performance and integration of functions, endoscopes are applicable to a wider range of clinical scenarios and have become essential tools for minimally invasive surgeries across numerous departments.
Driven by multiple factors and aligning with the era’s demand for minimally invasive surgery, China’s endoscopy market has continued to grow. According to Frost & Sullivan, as the market size of endoscopes in China continues to expand, domestic companies have gradually broken through technological barriers. Leveraging advantages in performance, pricing, and other aspects, the global market share of Chinese-made endoscopes is steadily increasing.
Data Source: Frost & Sullivan; Chart by VCBeat
Among the key players in the domestic endoscopy sector, Bosheng Medical has taken a leading role in import substitution, driven by its product advantages and strong industry reputation.In October 2023, the endoscopic image processors PX-850E and PX-850E-III, under Bosheng Medical, were included in the “Shenzhen Innovative Product Promotion and Application Catalog (First Batch of 2023),” becoming products prioritized for procurement and recommendation by government agencies.
Based on the publicly available data for the public 3D endoscope market in the first half of 2023, Shenzhen Bosheng Medical Technology Co., Ltd. is also accelerating its sales volume, ranking third in terms of winning bid amount, just behind the two major imported brands, and leading among domestic brands. This precisely confirms that Shenzhen Bosheng Medical Technology Co., Ltd., established in 2017, has become a new force in the research, development, manufacturing, and sales of high-end domestic minimally invasive medical equipment after years of dedicated R&D.
In terms of clinical application scenarios, the X1 host can be used forHepatobiliary Surgery, Gastrointestinal Surgery, Thyroid and Breast Surgery, Cardiothoracic Surgery, Neurosurgery, Otolaryngology, Urology, Gynecology, Orthopedicsmultiple departments, meeting the imaging needs for clinical diagnosis and treatment across various specialties.
According to reports, Bosheng Medical’s full product portfolio has been clinically applied in nearly 800 hospitals across China, earning widespread recognition from experts at tertiary Grade-A hospitals down to grassroots medical institutions. In the third year following the market approval of the PX-850E series, the clinical debut of the X1 platform also marked the 10,000th surgery performed using Bosheng Medical’s complete range of products.
In the medical industry, where patients’ lives are at stake, the value of innovation stems not only from technological leadership. Shenzhen Bosheng Medical Technology Co., Ltd. not only provides clinicians with more efficient diagnostic and therapeutic tools, but also leverages the cost-effectiveness of its domestically produced products to further promote the widespread adoption of endoscopic technology, thereby truly realizing value-based healthcare.
In recent years, China’s domestic medical technology industry has made significant strides in innovation; however, the pursuit of advancements in healthcare standards never ceases.Independent innovation is a crucial prerequisite for Bosheng Medical to maintain its long-term competitive advantage in the niche sector of rigid endoscopy.
According to data from Zhongcheng Medical Device Research Institute, the total sales revenue and market share of domestically produced medical endoscopes in healthcare institutions across China have shown a year-on-year increase from 2020 to 2022. The total sales revenue of domestically produced medical endoscopes reached nearly RMB 900 million in 2020 and rapidly grew to nearly RMB 3.7 billion in 2022, with a three-year compound annual growth rate (CAGR) as high as 102%.
Data Source: Zhongcheng Medical Device Research Institute; Chart by VCBeat
In the face of the rapidly growing endoscopy market, Bosheng MedicalFrom the 4K ultra-high-definition endoscope and 3D high-definition electronic laparoscope, which were successively approved for market launch in 2021, to the research-compatible 3D 4K fluorescence endoscope, and further to the X1 endoscopy platform, newly approved in 2024, the company has consistently aligned itself with the policy momentum driving the domestication of endoscopes in China, adhering to an integrated product design philosophy and continuously enhancing product quality and performance through iterative technological advancements and accumulation.
From a market-oriented perspective, integrated endoscopes can significantly reduce both upfront procurement costs and subsequent maintenance expenses. Furthermore, the integrated design greatly enhances operational convenience, minimizes the risk of connection errors by medical staff, and improves surgical precision and efficiency, thereby facilitating the advancement of minimally invasive surgery.
Of course, the X1 platform, which integrates 3D, 4K, and fluorescence technologies, will not be the endpoint for Shenzhen Bosheng Medical Technology Co., Ltd., but rather the starting point for the company to rank among the global leaders in the endoscopy industry.It is reported that Bosheng Medical, closely following clinical needs, is developing an upgraded version of the X1 platform—the X1-Pro Dual-Fluorescence Integrated Endoscopic Imaging Platform—which will further provide more personalized and customized multi-fluorescence navigation solutions based on clinical requirements.
After six years of accumulation, and alongside the trend toward minimally invasive and precise clinical surgeries as well as the rapid growth in endoscopic applications, Bosheng Medical has consistently remained at the forefront of the industry by leveraging its R&D strengths and integrated innovation.Looking ahead, Bosheng Medical will leverage its core strengths to integrate more innovative resources and strengthen close collaboration with clinical experts. By launching more product solutions that represent the forefront of minimally invasive surgical technologies, the company aims to meet the growing and diversified clinical demands, make a critical leap forward, and become a globally leading provider of minimally invasive medical devices.
References:
1. “2023: Bucking the Trend for Growth, a Host of Companies in This Sector Are Among the Few Winners This Year” VCBeat
2. “Focusing on Medical Technology Innovation: Bosheng Medical Successfully Achieves Domestic Production of Dual-Channel 3D Endoscopes,” Bosheng Medical
3. “China’s Endoscopy Market Saw Rapid Growth in 2023, with a Promising Future for 4K 3D Fluorescence Laparoscopes,” Zhongcheng Medical Devices